A Phase II Double-Blind Study of Delavirdine Mesylate ( U-90152 ) in Combination With Zidovudine ( AZT ) and/or Didanosine ( ddI ) Versus AZT and ddI Combination Therapy

NCT00000803 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

471

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Delavirdine mesylate
DRUG: Zidovudine
DRUG: Didanosine

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)